Core Viewpoint - Anteris Technologies Global Corp. is initiating a public offering of $200 million in common stock, with an additional $30 million option for underwriters, alongside a private placement of up to $90 million to Medtronic plc, aimed at supporting growth and clinical strategy execution [1][2][3]. Group 1: Offering Details - The company is offering $200 million of its common stock through a proposed underwritten public offering, with a 30-day option for underwriters to purchase an additional $30 million [1]. - Anteris has agreed to sell up to $90 million of common stock to Medtronic in a private placement, contingent on the completion of the public offering [2]. - The shares in the public offering are being offered under a shelf registration statement filed with the SEC, effective January 8, 2026 [5]. Group 2: Use of Proceeds - The net proceeds from the offering and private placement will be used to support the next stage of growth, including the PARADIGM Trial for the DurAVR Transcatheter Heart Valve and expansion of manufacturing capabilities [3]. - A portion of the proceeds will also fund ongoing research and development for v2vmedtech, inc., with the remainder allocated to working capital and general corporate purposes [3]. Group 3: Company Overview - Anteris Technologies is a global structural heart company focused on developing medical devices to restore heart function, with a significant presence in both Australia and the USA [9]. - The company's lead product, the DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [10].

Core Points - Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders to September 11, 2025, to allow more time for stockholder participation [1][2] - The Board of Directors recommends voting FOR the proposals in the definitive Proxy Statement filed with the SEC on August 18, 2025 [2] - The company’s lead product, the DurAVR Transcatheter Heart Valve, is designed to treat aortic stenosis and utilizes patented ADAPT tissue technology [8] Voting Details - Stockholders who have already voted do not need to take further action as their votes will remain counted [3] - Proxies must be submitted by 11:59 p.m. Eastern time on September 10, 2025, for Internet or telephone submissions, and by the close of business on the same date for mail submissions [4] - CDI holders must direct CDN to vote by 5:00 p.m. Central time on September 9, 2025 [5] Company Overview - Anteris Technologies is a global structural heart company focused on developing medical devices to restore heart function [7] - The company is based in Australia with a significant presence in Minneapolis, USA, and is committed to delivering solutions for structural heart disease [7]